Six Recent Advances in Tumor Immunotherapy Highlighted in Newly Filed Prospectus

1. MSD’s PD-1 Monoclonal Antibody Keytruda Approved for Marketing in China

On July 26, MSD announced that its PD-1 inhibitor pembrolizumab had officially received approval from China’s National Medical Products Administration.Approval, for the treatment of unresectable or metastatic melanoma that has failed first-line therapy.To date, pembrolizumab is the only PD-1 inhibitor approved in China for the treatment of advanced melanoma, marking the entry of melanoma treatment in China into the era of immunotherapy. Chinese drug regulatory authorities granted priority review status to this innovative therapeutic agent, which addresses significant unmet medical needs in China, thereby accelerating the approval process; it took just over five months from application submission to approval.

2. Significantly Prolongs OS in Head and Neck Cancer: Outstanding Phase 3 Clinical Data for MSD’s PD-1 Monoclonal Antibody

Merck Sharp & Dohme announced that its blockbuster immunotherapy Keytruda (pembrolizumab) inIn a Phase 3 Clinical Trial, as a first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma, significantly prolonged overall survival in patients, achieving the primary clinical endpoint. Notably, it is also the first anti-PD-1 therapy to demonstrate superior overall survival in the first-line treatment of this disease.The KEYNOTE-048 study enrolled 825 patients, who were randomized into multiple groups: one received Keytruda monotherapy, another received Keytruda in combination with chemotherapy, and the third received cetuximab plus chemotherapy. In an interim analysis conducted by an independent data monitoring committee, Keytruda monotherapy demonstrated a significantly longer overall survival compared to standard therapy. Its safety profile was consistent with data from previous studies. The detailed results of this study will be presented at upcoming medical conferences.

3. First Patient Dosed with BeiGene’s PD-1 Monoclonal Antibody in Combination with Chemotherapy as First-Line Treatment for Lung Cancer

On July 24, BeiGene announced that the first patient had been dosed in a Phase 3 clinical trial evaluating its investigational PD-1 antibody tislelizumab in combination with chemotherapy as a potential first-line treatment for patients in China with stage IIIB or IV non-squamous non-small cell lung cancer (NSCLC).This Phase 3 clinical trial was primarily designed to evaluate the potential impact of adding the investigational immuno-oncology drug tislelizumab to the current global standard of care, “platinum plus pemetrexed chemotherapy,” for patients with advanced non-squamous NSCLC.

Source: WuXi AppTec

Tislelizumab (BGB-A317) is an investigational humanized monoclonal antibody developed by BeiGene, belonging to a class of oncology immunotherapies known as immune checkpoint inhibitors.According to the introduction, this Phase 3, open-label, multicenter clinical trial is expected to enroll approximately 320 patients with untreated Stage IIIb or IV non-squamous NSCLC in mainland China. The trial aims to compare progression-free survival (PFS) as defined by RECIST v1.1 and assessed by an Independent Review Committee (IRC). Key secondary endpoints include overall survival, overall response rate, investigator-assessed PFS, safety, and tolerability.

4. CBT Conducts Phase 1b Clinical Trial of PD-1 Antibody CBT-501-01 (Genolimzumab)

CBT Pharmaceuticals (CBT) is an innovative biopharmaceutical company operating in both China and the United States, dedicated to developing combination therapies for oncology. The company recently announced the continuation of its Phase 1 clinical trial of CBT-501 (genolimzumab injection), initiating a Phase 1b study in patients with specific types of advanced or recurrent solid tumors. CBT-501 is a novel humanized IgG4 monoclonal antibody targeting the PD-1 membrane receptor on immune cells. Following a meeting of the Safety Review Committee (SRC), the SRC determined that the safety data accumulated to date indicate that CBT-501 is well tolerated and recommended a dosing regimen and development timeline. The Phase 1b study will evaluate four tumor types, with approximately 20 patients expected to be enrolled for each type. The ongoing clinical trials are currently being conducted in Australia.

5. Gossamer Bio Completes $230 Million Series B Financing, Focusing on Immunotherapy

Recently, Gossamer Bio, based in San Diego, United States, announced the completion of a $230 millionSeries B FinancingThis round of financing was led by Hillhouse Capital Group, with the funds raised to be used for advancing clinical trials of multiple preclinical and late-stage candidate drugs, as well as driving the company’s rapid growth. Gossamer Bio focuses on developing innovative immunology-based therapies, primarily targeting autoimmune diseases, allergy/inflammation, tumor immunology, and fibrotic diseases. Leveraging its expertise in the study of immunobiological mechanisms, the company pursues parallel development of multiple drug candidates by in-licensing promising immunology assets. Through this unique strategy, Gossamer Bio aims to overcome early-stage bottlenecks in drug development and accelerate the advancement of therapies that have the potential to significantly improve patients’ lives.

6. BMS Collaborates with Tsinghua University to Develop Drugs for Autoimmune Diseases and Cancer

Bristol-Myers Squibb (BMS) and Tsinghua University OfficiallyStrategic Cooperation Achieved, both parties will collaborate in the fields of autoimmune diseases and cancer to jointly discover and research therapeutic drugs with novel targets.According to reports, BMS and Tsinghua University will combine their respective scientific research strengths and professional expertise to focus on the validation of novel targets and to facilitate the discovery of early-stage drug candidates and their translation into clinical development. Under the collaboration agreement, the Institute for Cellular Immunotherapy (ICIT) at Tsinghua University will be responsible for conducting the research for these projects, while BMS will hold the right of first refusal for exclusive licensing rights to drugs developed by the center from these projects.

Bristol Myers Squibb and Tsinghua University have been engaged in scientific research collaboration since 2012, with a primary focus on autoimmune target discovery, structural biology research, and resolving the 3D protein structures of biomolecular targets. In March this year, BMS also signed a memorandum of understanding with ICIT on immunotherapy research and innovative drug development. The strategic partnership reached this time represents a further expansion and deepening of the long-standing cooperative relationship between the two parties.

References:

[1] Gossamer Bio Announces $230 Million Series B Financing

[2] KEYTRUDA® (pembrolizumab) Monotherapy Met a Primary Endpoint in the Phase 3 KEYNOTE-048 Trial, Significantly Improving OS as First-Line Therapy in Head and Neck Squamous Cell Carcinoma Patients Whose Tumors Expressed PD-L1 (CPS ≥20)

[3] CBT Pharmaceuticals Initiates Phase 1b Clinical Trial for Anti-PD-1 Antibody CBT-501-01 (genolimzumab injection) in Patients with Advanced Solid Tumors

(Translational Medicine Network 360zhyx.com)